Search Results

You are looking at 71 - 80 of 2,540 items for :

  • Refine by Access: All x
Clear All
Full access

Nila Alsheik, Zhaohui Su, Anna Lafontant, Gregory Donadio, Kathleen Troeger, Scott Pohlman, Melinda Talley, Vandana Menon, and Emily Conant

describe characteristics and outcomes of women who had only one screening mammogram versus those who had annual or biennial screens. Methods: A cloud-based big data platform is being used to integrate and transform data from electronic medical records

Full access

Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre, and Natalie S. Callander

obesity and transplant outcomes in MM patients in the era of modern therapy, routine post-transplant maintenance, and genetic-based risk stratification. Methods: We retrospectively reviewed consecutive patients undergoing autoPBSCT for MM at our

Full access

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

validated 12 – 15 ; however, it is considered a screening measure and not intended or appropriate for diagnostic purposes. Results in this study focus on outcomes regarding pain, fatigue, depression, anxiety, and well-being. Canadian Problem Checklist

Full access

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

-adjusted incidence of vSCC is 2.5 per 100,000 women. 3 The most significant prognostic factor for vSCC is lymph node status. 4 , 5 Other factors associated with poor outcomes include age, tumor diameter, tumor depth, tumor class, histologic grade, lymphovascular

Full access

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

These entities stipulate 2 criteria to establish surrogacy: (1) good correlation between the surrogate endpoint and the final outcome (individual-level association) and (2) good correlation between the treatment effect on the surrogate endpoint and the

Full access

Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst

, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2 , with corresponding cumulative

Full access

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching

long-term survival outcomes among patients with general BC and certain subtypes including triple negative BC (TNBC). To update and extend the evidence to assess the association of pCR and survival outcomes in TNBC, this study reviewed and summarized

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy

Full access

Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw

potential of missing data or bias), and little attention to patients with advanced disease who received opioids for pain management rather than as a perioperative anesthetic. To provide a better assessment of the impact of opioid use on outcomes of patients

Full access

Jessica D. McDermott, Megan Eguchi, Rustain Morgan, Arya Amini, Julie A. Goddard, Evelinn A. Borrayo, and Sana D. Karam

Background Approximately 65,000 new cases of head and neck cancer (HNC) are diagnosed in the United States annually, with 13,500 cancer-related deaths. 1 HNC has discrepancies in presentations and outcomes across different racial and ethnic cohorts